Establishment of a model for predicting the efficacy of third-generation cephalosporin in treatment of community-acquired spontaneous bacterial peritonitis

Longchuan ZHU; Wei WU; Bo ZOU; Dakai GAN; Xue LIN; Wei ZHOU; Molong XIONG

doi:10.3969/j.issn.1001-5256.2022.11.012

Volume 38 Issue 11

Nov. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(11): 2499-2504

PDF( 2187 KB)

Establishment of a model for predicting the efficacy of third-generation cephalosporin in treatment of community-acquired spontaneous bacterial peritonitis

DOI: 10.3969/j.issn.1001-5256.2022.11.012

Longchuan ZHU^{1a
,
,
,},
Wei WU²,
Bo ZOU^1a,
Dakai GAN^1a,
Xue LIN^1a,
Wei ZHOU^1b,
Molong XIONG^1a

1a.
Department of Liver Disease, The Ninth Hospital of Nanchang, Nanchang 330002, China
1b.
Department of Information Technology, The Ninth Hospital of Nanchang, Nanchang 330002, China
2.
Department of Digestion, Children's Hospital of Jiangxi Province, Nanchang 330000, China

Research funding:

Key Research and Development Program of Jiangxi Province (20181BBG78010)

More Information

Corresponding author: ZHU Longchuan, zlcy1984@sina.com(ORCID: 0000-0002-4461-6195)
Received Date: 2022-04-05
Accepted Date: 2022-05-07
Published Date: 2022-11-20

Abstract

Abstract

Objective To investigate the factors for predicting the efficacy of third-generation cephalosporin (3^rd GC) in the treatment of community-acquired spontaneous bacterial peritonitis (CASBP), and to establish and validate an efficacy predictive model for 3^rd GC in the treatment of CASBP. Methods A retrospective analysis was performed for the clinical data of the patients with liver cirrhosis and CASBP who received 3^rd GC monotherapy for initial treatment in The Ninth Hospital of Nanchang, and according to their treatment outcome, they were divided into non-response group and response group. The patients hospitalized from 2013 to 2018 were included in the modeling cohort (55 patients the non-response group and 110 in the response group), and those hospitalized from 2019 to 2020 were included in the validation cohort (17 patients in the non-response group and 43 in the response group). In the modeling cohort, the two groups were compared in terms of the indices including general information, underlying diseases, past history, clinical manifestation, and laboratory test results. Univariate analyses (the t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups; the chi-square test or the Fisher's exact test was used for comparison of categorical data between groups) and a binary Logistic regression analysis were used to identify efficacy predictors, and an efficacy predictive model was established based on the logistic regression equation. The receiver operating characteristic (ROC) curve was plotted to perform internal and external validations of the model in the modeling cohort and the validation cohort, respectively. Results The study population had a mean age of 51.6±12.0 years, and male patients accounted for 80.0%; hepatitis B was the main cause of liver cirrhosis (66.7%), and 3^rd GC had an overall response rate of 68.0%. In the modeling cohort, compared with the response group, the non-response group had significantly lower proportion of patients with the first onset of SBP, polymorphonuclear (PMN) count in ascites, and leukocyte count in ascites (all P < 0.05), as well as significantly higher proportion of patients with exposure to broad-spectrum antibiotic and platelet count (both P < 0.05). The Logistic regression analysis showed that the first onset of SBP (odds ratio [OR]=0.158, 95% confidence interval [CI]: 0.064-0.392, P < 0.001), ascites PMN count (OR=0.728, 95%CI: 0.530-0.998, P=0.046), exposure to broad-spectrum antibiotic (OR=9.152, 95%CI: 1.513-55.351, P=0.016), and platelet count (OR=1.012, 95%CI: 1.006-1.019, P < 0.001) were independent predictive factors for non-response to 3^rd GC. The efficacy predictive model had an area under the ROC curve (AUC) of 0.840, and based on the maximum Youden index, predictive score ≥ 0.207 was the optimal cut-off value for predicting non-response, with a corresponding Youden index of 0.536, a sensitivity of 89.1%, a specificity of 63.6%, a positive predictive value of 55.1%, and a negative predictive value of 92.1%. This model had an AUC of 0.837 in the validation cohort. Conclusion The first onset of SBP and higher ascites PMN count are the protective factors against non-response to 3^rd GC for the treatment of CASBP, and exposure to broad-spectrum antibiotic and higher platelet count are the risk factors for such non-response. The model established for predicting the efficacy of 3^rd GC in the treatment of CASBP has good predictive performance and thus holds promise for clinical application.
- Liver Cirrhosis,
- Peritonitis,
- Community-Acquired Infections,
- Cephalosporins,
- Logistic Models

FullText(HTML)

References(15)

References

[1]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of ascites and complications in cirrhosis[J]. J Chin Hepatol, 2017, 33(10): 1847-1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003. 中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南[J]. 临床肝胆病杂志, 2017, 33(10): 1847-1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003.
[2]	BIGGINS SW, ANGELI P, GARCIA-TSAO G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2021, 74(2): 1014-1048. DOI: 10.1002/hep.31884.
[3]	FIORE M, GENTILE I, MARAOLO AE, et al. Are third-generation cephalosporins still the empirical antibiotic treatment of community-acquired spontaneous bacterial peritonitis? A systematic review and meta-analysis[J]. Eur J Gastroenterol Hepatol, 2018, 30(3): 329-336. DOI: 10.1097/MEG.0000000000001057.
[4]	PUGH RN, MURRAY-LYON IM, DAWSON JL, et al. Transection of the oesophagus for bleeding oesophageal varices[J]. Br J Surg, 1973, 60(8): 646-649. DOI: 10.1002/bjs.1800600817.
[5]	KAMATH PS, WIESNER RH, MALINCHOC M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001, 33(2): 464-470. DOI: 10.1053/jhep.2001.22172.
[6]	SUNJAYA DB, LENNON RJ, SHAH VH, et al. Prevalence and predictors of third- generation cephalosporin resistance in the empirical treatment of spontaneous bacterial peritonitis[J]. Mayo Clin Proc, 2019, 94(8): 1499-1508. DOI: 10.1016/j.mayocp.2018.12.036..
[7]	PEDUZZI P, CONCATO J, KEMPER E, et al. A simulation study of the number of events per variable in Logistic regression analysis[J]. J Clin Epidemiol, 1996, 49(12): 1373-1379. DOI: 10.1016/s0895-4356(96)00236-3.
[8]	TAY P, XIAO J, TAN D, et al. An epidemiological meta-analysis on the worldwide prevalence, resistance, and outcomes of spontaneous bacterial peritonitis in cirrhosis[J]. Front Med (Lausanne), 2021, 8: 693652. DOI: 10.3389/fmed.2021.693652.
[9]	SARWAR S, TARIQUE S, WARIS U, et al. Cephalosporin resistance in community acquired spontaneous bacterial peritonitis[J]. Pak J Med Sci, 2019, 35(1): 4-9. DOI: 10.12669/pjms.35.1.17.
[10]	Ministry of Health of the People's Republic of China. Regulations for clinical application of antibacterial agents[J]. Chin J Clin Infect Dis, 2012, 5(4): 193-196. DOI:10.3760/cma.j.issn. 1674-2397.2012.04.001. 中华人民共和国卫生部. 抗菌药物临床应用管理办法[J]. 中华临床感染病杂志, 2012, 5(4): 193-196. DOI: 10.3760/cma.j.issn.1674-2397.2012.04.001.
[11]	ZHU LC, GAN DK, HU QQ, et al. Predictive factors for third-generation cephalosporin- resistant spontaneous bacterial peritonitis[J]. J Chin Hepatol, 2019, 35(7): 1501-1504. DOI: 10.3969/j.issn.1001-5256.2019.07.016. 朱龙川, 甘达凯, 胡青青, 等. 第三代头孢菌素耐药的自发性细菌性腹膜炎发生的预测因素[J]. 临床肝胆病杂志, 2019, 35(7): 1501-1504. DOI: 10.3969/j.issn.1001-5256.2019.07.016.
[12]	ARIZA X, LORA-TAMAYO J, CASTELLOTE J, et al. Polymorphonuclear counts in ascitic fluid and microorganisms producing spontaneous bacterial peritonitis: an under-recognized relationship[J]. Scand J Gastroenterol, 2013, 48(10): 1213-1221. DOI: 10.3109/00365521.2013.832367.
[13]	ZHANG GY, TIAN CY, HU H. Recent progress in immune dysfunction of neutrophils in patients with cirrhosis[J]. Chin Gen Pract, 2021, 24(21): 2734-2743. DOI: 10.12114/j.issn. 1007-9572.2021.00.457. 张国远, 田彩云, 胡晗. 肝硬化患者中性粒细胞免疫功能障碍的研究进展[J]. 中国全科医学, 2021, 24(21): 2734-2743. DOI: 10.12114/j.issn.1007-9572.2021.00.457.
[14]	MISHRA D, DAS AK, CHAPAGAIN RH, et al. Thrombocytosis as a predictor of serious bacterial infection in febrile infants[J]. J Nepal Health Res Counc, 2019, 16(41): 401-404. DOI: 10.33314/jnhrc.v16i41.1673.
[15]	YUAN SN, ZHAO JJ, HAN XY, et al. Influence of bacterial and fungal infections on platelets[J]. Chin J Nosocomiol, 2016, 26(22): 5083-5086. DOI: 10.11816/cn.ni.2016-154312. 袁胜男, 赵俊暕, 韩晓燕, 等. 细菌与真菌感染对血小板的影响研究[J]. 中华医院感染学杂志, 2016, 26(22): 5083-5086. DOI: 10.11816/cn.ni.2016-154312.

Relative Articles

[1]	Longchuan ZHU, Wei WU, Dakai GAN, Wei ZHANG, Yizhen XU, Molong XIONG. Clinical application value of a predictive model for the efficacy of third-generation cephalosporin in treatment of community-acquired spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2024, 40(2): 306-311. doi: 10.12449/JCH240214
[2]	Xiumin CHEN, Shenglong LIN, Xiangmei WANG, Huaxi MA, Dongqing ZHANG, Ziyuan LIAO, Minghua LIN, Haibing GAO. Association of energy metabolic markers with the short-term risk of spontaneous bacterial peritonitis in patients with decompensated hepatitis B virus-related liver cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(6): 1311-1316. doi: 10.3969/j.issn.1001-5256.2022.06.018
[3]	Yu LIU, Yuyi ZHANG, Ying ZOU, Wei YUAN, Hongying GUO, Xue MEI, Jiefei WANG, Zhiping QIAN. Association between intestinal microecology and spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2021, 37(2): 425-428. doi: 10.3969/j.issn.1001-5256.2021.02.037
[4]	Zhenjiao GAO, Xingshun QI, Hongyu LI, Xiaozhong GUO. A case of spontaneous bacterial peritonitis caused by Neisseria. subflava in liver cirrhosis[J]. Journal of Clinical Hepatology, 2021, 37(1): 153-155. doi: 10.3969/j.issn.1001-5256.2021.01.030
[5]	Lin DongYi, Peng Bo, Zheng JingHui, Wang ZongYu, Li HanZhong, He JianBo, Li KeZhi, Wu GuoBin, Chen Chuang. Value of a logistic regression model based on the clinical features of liver cancer in judging the traditional Chinese medicine syndrome types of primary liver cancer[J]. Journal of Clinical Hepatology, 2020, 36(6): 1293-1298. doi: 10.3969/j.issn.1001-5256.2020.06.021
[6]	Xue ShuWen, Zhao QianShu, Li XiaoKe, Yang QianQian, Zhou Qi, Guo XiaoLin, Ji HuiFan. A case of recurrent fever and lumbago in hepatic cirrhosis complicated by spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2289-2291. doi: 10.3969/j.issn.1001-5256.2019.10.032
[7]	Li BeiLing, Zhong GuoTao, Chen JinJun. Current status of the diagnose and treatment of spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2019, 35(9): 2079-2081. doi: 10.3969/j.issn.1001-5256.2019.09.043
[8]	Zhang YaNan, Jiang Chang, Xu Ying, Gao YanHang. Early diagnosis of spontaneous bacterial peritonitis in liver cirrhosis[J]. Journal of Clinical Hepatology, 2019, 35(8): 1851-1853. doi: 10.3969/j.issn.1001-5256.2019.08.045
[9]	Huang YunYi, Wang XianBo. Establishment of a predictive model of death within 30 days for patients with liver cirrhosis and bacterial ascites[J]. Journal of Clinical Hepatology, 2019, 35(11): 2472-2477. doi: 10.3969/j.issn.1001-5256.2019.11.017
[10]	Zhu LongChuan, Gan DaKai, Hu QingQing, Xiong MoLong. Predictive factors for third-generation cephalosporin-resistant spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2019, 35(7): 1501-1504. doi: 10.3969/j.issn.1001-5256.2019.07.016
[11]	Song YuanYuan, Jiang YuYong. Research advances in diagnosis and treatment of spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2016, 32(6): 1188-1191. doi: 10.3969/j.issn.1001-5256.2016.06.040
[12]	Yang ZhengMao, Shi WenJuan, Zhou Jian, Wang ZhaoXun. Curative effect of peritoneal lavage in treatment of cirrhotic patients with spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2015, 31(3): 384-386. doi: 10.3969/j.issn.1001-5256.2015.03.017
[13]	Zhang JuLing, Geng Wei, Cui EnBo, Yuan Yuan, Zhang ChengLong, Chen SuMing, Jia TianYe, Wang Huan, Bao ChunMei, Qu Fen. Analysis of pathogenic features of liver cirrhosis with spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2015, 31(3): 407-412. doi: 10.3969/j.issn.1001-5256.2015.03.023
[14]	Gu LiLi, Wang XianBo. Research progress in noninvasive regression models for liver fibrosis in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2014, 30(7): 691-694. doi: 10.3969/j.issn.1001-5256.2014.07.032
[15]	Cui YanPing, Liu FengHua, Shi QingFeng, Zhao HongKui, Wang SiKui. Logistic regression analysis of prognostic factors in 106 acute-on-chronic liver failure patients with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2014, 30(10): 992-995. doi: 10.3969/j.issn.1001-5256.2014.10.005
[16]	Zhang ZhanQing, Lu Wei, Wang YanBing, Jia XiaoFang, Zhang LiJun, Ding RongRong, Zhou XinLan, Feng YanLing. Diagnosis of hepatic fibrosis in hepatitis B patients by logistic regression modeling based on plasma amino acid ratio and age[J]. Journal of Clinical Hepatology, 2013, 29(5): 330-335.
[17]	Wu HaiQing, Wang Hui. Diagnosis and treatment of spontaneous bacterial peritonitis in patients with liver ascites[J]. Journal of Clinical Hepatology, 2012, 28(9): 651-653.
[18]	Li RuGui, Tan HuaBing, Zhan GuoQing, Zhang WeiWei, Hu Bo. A retrospective analysis of the factors influencing the prognosis of liver cirrhosis combined with spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2011, 27(2): 170-173.
[19]	Mou XiaoHui. Management of spontaneous bacterial peritonitis in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2011, 27(10): 1015-1018.
[20]	Liang Jing, Kan ZhiChao, Zhang JianDong. The clinical characteristics and treatment of liver failure patients with spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2010, 26(6): 621-623.

Supplements(0)

Cited By

Cited by

Periodical cited type(7)

1.	张旭，余嘉惠，王丽娜. 中医药防治慢性胰腺炎胰腺纤维化的机制研究. 中医学报. 2024(04): 758-764 .
2.	刘鑫，邱明亮，胡晓凤，彭婷，高月，张琦. 雷公藤甲素抗器官纤维化作用机制研究进展. 中草药. 2024(10): 3569-3578 .
3.	纪晓丹，龚彪，李兴佳，吕婵，徐莹. 中医药治疗胰腺纤维化的临床对策及研究进展. 临床肝胆病杂志. 2023(09): 2258-2264 . 本站查看
4.	李雪丽，刘钊. 雷公藤甲素通过调控AMPK/mTOR通路抑制脂肪细胞和巨噬细胞炎症机制研究. 辽宁中医药大学学报. 2022(12): 24-29+237 .
5.	戚潇禹，刘璐佳，杨阳，于海洋，王有鹏. 基于TGF-β_1/Smads信号通路中医药抗纤维化研究进展. 辽宁中医药大学学报. 2021(01): 58-62 .
6.	陈鑫，张永萍，徐剑，刘耀. 雷公藤甲素的现代研究进展. 贵州中医药大学学报. 2021(05): 85-89 .
7.	夏时海. 氧化苦参碱在防治胰腺纤维化的研究前景及临床应用价值. 世界华人消化杂志. 2020(17): 819-826 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (405) PDF downloads(43)

Establishment of a model for predicting the efficacy of third-generation cephalosporin in treatment of community-acquired spontaneous bacterial peritonitis

DOI: 10.3969/j.issn.1001-5256.2022.11.012